BRIEF published on 09/11/2026 at 20:45, 16 hours 44 minutes ago IntegraGen: two takeover bids filed in receivership Judicial Reorganization Genomics IntegraGen Resumption Commercial Court Of Évry
BRIEF published on 09/11/2026 at 20:45, 16 hours 44 minutes ago IntegraGen : deux offres de reprise déposées en redressement judiciaire Reprise Redressement Judiciaire Génomique IntegraGen Tribunal De Commerce D'Évry
PRESS RELEASE published on 09/11/2026 at 20:40, 16 hours 49 minutes ago Informations privilégiées / Autres communiqués IntegraGen reçoit deux offres de reprise dans le cadre de son redressement judiciaire. Health In Code et ABL Diagnostics proposent de reprendre les activités et actifs de la société spécialisée en génomique Cancer Redressement Judiciaire Offres De Reprise Génomique IntegraGen
BRIEF published on 06/15/2026 at 20:31, 2 months 26 days ago IntegraGen is heading towards receivership to ensure its survival. Sustainability Judicial Reorganization Genomics Industrial Partnerships Strategic Activities
BRIEF published on 06/15/2026 at 20:31, 2 months 26 days ago IntegraGen se dirige vers un redressement judiciaire pour assurer sa pérennité Pérennité Redressement Judiciaire Génomique Partenariats Industriels Activités Stratégiques
PRESS RELEASE published on 06/15/2026 at 20:26, 2 months 26 days ago Informations privilégiées / Autres communiqués IntegraGen annonce la conversion de sa procédure de sauvegarde en redressement judiciaire pour poursuivre les discussions avec des acteurs intéressés par ses activités Sauvegarde Redressement Judiciaire Procédure Collective Génomique IntegraGen
BRIEF published on 02/20/2026 at 20:20, 6 months 19 days ago IntegraGen: Annual Review and Continued Strategic Refocusing Revenue Treasury Certifications Profitability Biopharma
BRIEF published on 02/20/2026 at 20:20, 6 months 19 days ago IntegraGen : Bilan Annuel et Poursuite du Recentrage Stratégique Chiffre D'affaires Rentabilité Certifications Trésorerie Biopharma
PRESS RELEASE published on 02/20/2026 at 20:15, 6 months 19 days ago Informations privilégiées / Information sur chiffre d’affaires annuel IntegraGen annonce un chiffre d'affaires annuel de 5 M€ pour 2025, une trésorerie de 1,1 M€ et un recentrage sur les études cliniques biopharma Chiffre D'affaires Trésorerie Biopharma Études Cliniques IntegraGen
BRIEF published on 10/29/2025 at 17:50, 10 months 13 days ago IntegraGen : Résultats en Baisse, Réduction des Dépenses au 1er Semestre 2025 Résultats Financiers Trésorerie Génomique Réduction Coûts Certification CLIA/CAP
Published on 09/12/2026 at 02:35, 10 hours 54 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 29 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 24 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 4 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 29 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 5 hours 59 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 14 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 19 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 44 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 14 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 17 hours ago Availability of the 2026 Interim Financial Report
